<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gene test interpretation: &lt;i&gt;ATM&lt;/i&gt; (ataxia-telangiectasia, breast cancer, and pancreatic cancer susceptibility gene)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gene test interpretation: <i>ATM</i> (ataxia-telangiectasia, breast cancer, and pancreatic cancer susceptibility gene)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gene test interpretation: <i>ATM</i> (ataxia-telangiectasia, breast cancer, and pancreatic cancer susceptibility gene)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Puneet Opal, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Beth N Peshkin, MS, CGC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne Slavotinek, MBBS, PhD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 19, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H284318600"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This monograph summarizes the interpretation of genetic testing for <em>ATM</em>, the gene associated with ataxia-telangiectasia. It does <strong>not</strong> discuss indications for testing and is not intended to replace clinical judgment in the decision to test or in the care of the tested person. These subjects are discussed separately [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H995608215"><span class="h1">OVERVIEW</span></p><p class="headingAnchor" id="H2692559800"><span class="h2">How to read the report</span><span class="headingEndMark"> — </span>The checklist provides important caveats for genetic testing (<a class="graphic graphic_table graphicRef122437" href="/d/graphic/122437.html" rel="external">table 1</a>). Any result obtained for research or by direct-to-consumer testing that has clinical implications for the tested individual or their relatives should be repeated in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory or comparable accreditation body in other jurisdictions, with verified patient identification.</p><p class="headingAnchor" id="H2072228645"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>Ataxia-telangiectasia (AT) is an autosomal recessive disorder characterized by progressive cerebellar degeneration, oculocutaneous telangiectasias, immunodeficiency, susceptibility to cancer, and radiation sensitivity. The disorder is caused by biallelic (homozygous or compound heterozygous) pathogenic variants in the ataxia-telangiectasia mutated (<em>ATM</em>) gene on chromosome 11q22, which lead to defective DNA repair mechanisms and genome instability. </p><p>The <em>ATM</em> gene product, ATM kinase, is involved in the detection of DNA damage and plays an important role in cell cycle progression.</p><p>Biallelic, pathogenic (disease-causing) variants <strong>affecting both</strong> <em>ATM </em>alleles are required to develop ataxia-telangiectasia. Typically, one pathogenic variant is inherited from each parent. </p><p>Heterozygosity for a disease variant affecting one <em>ATM</em> allele increases susceptibility to breast, pancreatic, and possibly other cancers. Therefore, at-risk relatives should be offered genetic counseling so that they can be counseled appropriately about their risks. (See  <a class="medical medical_review" href="/d/html/785.html" rel="external">"Overview of hereditary breast and ovarian cancer syndromes", section on 'ATM'</a>.)</p><p class="headingAnchor" id="H3939314763"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H1728267399"><span class="h2">Biallelic disease variants</span><span class="headingEndMark"> — </span>The ataxia-telangiectasia (AT) phenotype results from biallelic loss-of-function variants leading to absent or defective ATM kinase. Individuals may be homozygotes or compound heterozygotes for these disease variants. Symptom severity depends on residual ATM activity, which can be gauged by the type of variant. The following phenotypes are generally recognized (see  <a class="medical medical_review" href="/d/html/6233.html" rel="external">"Ataxia-telangiectasia", section on 'Clinical manifestations'</a>):</p><p class="headingAnchor" id="H2294317212"><span class="h3">Classic AT</span><span class="headingEndMark"> — </span>The classic and most severe form of AT usually presents either at birth, with partial combined immunodeficiency, or in early childhood, when progressive cerebellar dysfunction and ocular signs become apparent. Young children develop progressive cerebellar ataxia, abnormal eye movements, extrapyramidal motor dysfunction, and oculocutaneous telangiectasias. Progressive pulmonary disease and lymphoid malignancies are major causes of morbidity and mortality.</p><p class="headingAnchor" id="H744073551"><span class="h3">Variant AT</span><span class="headingEndMark"> — </span>Variant AT presents slightly later, by the age of 10 years in most cases, with milder cerebellar dysfunction and extrapyramidal movement disorders (eg, tremor, dystonia). Compared with classic AT, cancer tends to occur later in life and may include a higher proportion of solid tumors. </p><p class="headingAnchor" id="H230517153"><span class="h3">Disease associations</span></p><p class="headingAnchor" id="H2394691500"><span class="h4">Neurologic manifestations</span><span class="headingEndMark"> — </span>Ataxia is often the earliest neurologic manifestation of AT. Mild to moderate cognitive impairment is frequently present early in the course of AT, and cognitive deficits may become more widespread and severe in the later stages of AT [<a href="#rid2">2</a>]. Visual performance progressively deteriorates and patients may have extrapyramidal motor difficulties. (See  <a class="medical medical_review" href="/d/html/6233.html" rel="external">"Ataxia-telangiectasia", section on 'Neurologic manifestations'</a>.)</p><p class="headingAnchor" id="H1855689783"><span class="h4">Telangiectasias</span><span class="headingEndMark"> — </span>Telangiectasias of blood vessels are seen primarily in the eyes (on the bulbar conjunctivae) and on exposed areas of the skin, typically the pinnae, nose, face, and neck. Additional skin lesions include café-au-lait macules, hypopigmented macules, melanocytic nevi, and facial papulosquamous rash. (See  <a class="medical medical_review" href="/d/html/6233.html" rel="external">"Ataxia-telangiectasia", section on 'Telangiectasias and skin findings'</a>.)</p><p class="headingAnchor" id="H1394165772"><span class="h4">Immune deficiency</span><span class="headingEndMark"> — </span>Immune deficiency, affecting both cellular and humoral immunity, occurs in approximately 70 percent of patients with AT. The most common complication is recurrent sinopulmonary infections. (See  <a class="medical medical_review" href="/d/html/6233.html" rel="external">"Ataxia-telangiectasia", section on 'Immune deficiency'</a>.)</p><p class="headingAnchor" id="H111013391"><span class="h4">Pulmonary disease</span><span class="headingEndMark"> — </span>Progressive pulmonary disease is a major cause of morbidity and mortality in patients with AT. Three major types of pulmonary involvement are seen (see  <a class="medical medical_review" href="/d/html/6233.html" rel="external">"Ataxia-telangiectasia", section on 'Pulmonary disease'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent sinopulmonary infections and bronchiectasis</p><p class="bulletIndent1"><span class="glyph">●</span>Interstitial lung disease/pulmonary fibrosis</p><p class="bulletIndent1"><span class="glyph">●</span>Neuromuscular abnormalities, including dysphagia, aspiration, and respiratory muscle weakness</p><p></p><p class="headingAnchor" id="H2503605695"><span class="h4">Cancer</span><span class="headingEndMark"> — </span>Above age 10 years, the incidence of cancer in patients with AT is 1 percent per year; overall, approximately 10 to 25 percent of patients will develop malignancy [<a href="#rid3">3-5</a>]. The majority (85 percent) are lymphomas and acute leukemias. Among patients who survive to adulthood (&gt;20 years), there also appears to be an increase in the risk of solid tumors as compared with the general population, including breast, liver, gastric, and esophageal cancers. (See  <a class="medical medical_review" href="/d/html/6233.html" rel="external">"Ataxia-telangiectasia", section on 'Malignancy'</a>.)</p><p class="headingAnchor" id="H1438723409"><span class="h2">Monoallelic <i>ATM </i>disease variant (AT carrier)</span><span class="headingEndMark"> — </span>Heterozygotes for a single pathogenic AT variant have none of the classic manifestations of AT, but they are at increased risk for some cancers. It is important to note whether the specific variant identified is associated with a unique profile of cancer risks. However, most <em>ATM</em> pathogenic or likely pathogenic variants are associated with an increased risk for female breast cancer and pancreatic cancer, which can occur at younger ages compared with the general population [<a href="#rid6">6</a>]. <em>The risk for ovarian cancer may also be slightly increased in AT carriers. The risk of other solid cancers (eg, gastric, male breast, colorectal, and melanoma) may also be elevated, but there are insufficient data to provide absolute </em>risks [<a href="#rid7">7</a>]<em>. </em>(See  <a class="medical medical_review" href="/d/html/6233.html" rel="external">"Ataxia-telangiectasia", section on 'Heterozygotes'</a>.)</p><p class="headingAnchor" id="H2315053631"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H2035608533"><span class="h2">Patients with ataxia-telangiectasia</span></p><p class="headingAnchor" id="H3480401701"><span class="h3">General measures for AT</span><span class="headingEndMark"> — </span>Management of patients with AT is supportive and symptomatic, as there are no disease-modifying treatments available (<a class="graphic graphic_algorithm graphicRef138554" href="/d/graphic/138554.html" rel="external">algorithm 1</a>) [<a href="#rid2">2,8</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>All patients should undergo at least one comprehensive immunologic evaluation to measure both humoral and cellular immune function. Patients with immunodeficiency require additional preventive measures and should be followed by an immunologist whenever possible. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vaccinations that are safe and especially important in patients with AT include pneumococcus, inactivated influenza, human papillomavirus (HPV), and coronavirus disease 2019 (COVID-19). Live vaccines are contraindicated in most patients with AT due to partial combined immunodeficiency. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Physical and occupational therapy are critical for maintaining the maximum possible level of function. Swallowing function should be evaluated by an experienced team while minimizing radiation exposure. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients require routine chest therapy for secretion clearance, regular monitoring of pulmonary function, and antibiotics for acute infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diagnostic tests involving radiation exposure, including radiographs and computed tomography (CT), should be avoided when possible. </p><p></p><p class="headingAnchor" id="H1147391944"><span class="h3">Cancer screening</span></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with AT are at increased risk of lymphoid and other malignancies, but protocols for early detection of hematologic malignancies have not been established. Clinicians should maintain heightened awareness for easy bruising, persistently swollen lymph nodes, weight loss, or unexplained fevers. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Due to the risk of breast cancer in females with AT who survive into adulthood, some experts suggest beginning yearly breast magnetic resonance imaging (MRI) at age 25 years and avoiding mammography in order to limit radiation exposure. (See  <a class="medical medical_review" href="/d/html/6233.html" rel="external">"Ataxia-telangiectasia", section on 'Cancer surveillance'</a>.)</p><p></p><p class="headingAnchor" id="H2837874605"><span class="h3">Use of chemoradiation therapy</span><span class="headingEndMark"> — </span>Conventional doses of radiotherapy can cause severe reactions and are potentially lethal in patients with AT. Radiotherapy should be performed only in rare circumstances in patients with AT and only with reduced doses and careful monitoring. Patients are also particularly sensitive to chemotherapeutic agents that cause double-stranded breaks in DNA. (See  <a class="medical medical_review" href="/d/html/6233.html" rel="external">"Ataxia-telangiectasia", section on 'Cancer management'</a>.)</p><p class="headingAnchor" id="H1422830084"><span class="h2">Monoallelic <i>ATM </i>disease variants (AT carriers)</span></p><p class="bulletIndent1"><span class="glyph">●</span>We typically initiate annual mammography with tomography and annual MRI with contrast, starting at age 40 years [<a href="#rid9">9</a>]. Screening recommendations may be modified based on genotype and family history (<a class="graphic graphic_algorithm graphicRef138554" href="/d/graphic/138554.html" rel="external">algorithm 1</a>). In light of the higher risk of breast cancer associated with the c.7271T&gt;G variant, surveillance may begin at age 25 years with breast MRI and the addition of annual mammography beginning at age 30 [<a href="#rid6">6</a>]. There is insufficient evidence to uniformly recommend risk-reducing mastectomy, although for those with a personal or family history of breast cancer (eg, conferring &gt;20 percent lifetime risk of breast cancer by a model in women without cancer), it may be reasonable for carriers to consider this option. (See  <a class="medical medical_review" href="/d/html/785.html" rel="external">"Overview of hereditary breast and ovarian cancer syndromes", section on 'ATM'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those with a family history of pancreatic cancer, pancreatic cancer screening with endoscopic ultrasound (EUS) and/or contrast-enhanced MRI/magnetic resonance cholangiopancreatography (MRCP) is offered starting at 45 to 50 years of age or 10 years earlier than the earliest exocrine pancreatic cancer diagnosis in the family [<a href="#rid9">9,10</a>]. (See  <a class="medical medical_review" href="/d/html/83943.html" rel="external">"Familial risk factors for pancreatic cancer and screening of high-risk patients", section on 'Ataxia-telangiectasia'</a> and  <a class="medical medical_review" href="/d/html/83943.html" rel="external">"Familial risk factors for pancreatic cancer and screening of high-risk patients", section on 'Screening modalities'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Discussion of screening for prostate cancer with annual prostate-specific antigen (PSA) screening beginning at age 40 years, especially in those with a family history of prostate cancer, and after discussing the potential benefits, risks, and limitations with their provider [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/112282.html" rel="external">"Genetic risk factors for prostate cancer", section on 'Guidelines from expert groups'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those who have a family history of ovarian cancer, we discuss the potential risks and benefits of risk-reducing bilateral salpingo-oophorectomy. However, pathogenic variants in <em>ATM </em>do not appear to confer a significantly increased risk for ovarian cancer. (See  <a class="medical medical_review" href="/d/html/785.html" rel="external">"Overview of hereditary breast and ovarian cancer syndromes", section on 'ATM'</a>.)</p><p></p><p class="headingAnchor" id="H3552238993"><span class="h2">Other important considerations</span></p><p class="headingAnchor" id="H2848046211"><span class="h3">Reproductive counseling</span><span class="headingEndMark"> — </span>Preconception counseling is appropriate for individuals with AT and AT carriers who are considering childbearing. Partners of individuals with AT and partners of carriers may elect to undergo genetic testing to determine if any pathogenic or likely pathogenic variants in <em>ATM</em> are present that would confer a risk of AT in offspring. If there is a risk for AT, some may elect to conceive using donor gametes or in vitro fertilization (IVF) with preimplantation genetic testing (PGT). Testing is also available during a pregnancy or after birth.</p><p class="headingAnchor" id="H1366022108"><span class="h3">Genetic testing of at-risk relatives</span><span class="headingEndMark"> — </span>Full siblings of the index patient with biallelic germline <em>ATM</em> variants have a 25 percent chance of inheriting both <em>ATM</em> variants (and having AT), a 50 percent chance of being a carrier (heterozygote) of a single <em>ATM</em> variant, and a 25 percent chance of being unaffected and not being a carrier. (See <a class="local">'Genetics'</a> above.)</p><p>Genetic counseling and testing should be offered to all at-risk relatives (siblings, parents, children, aunts, and uncles) through a genetics provider or a provider with expertise in genetic evaluation and counseling. (See <a class="local">'Resources'</a> below.)</p><p class="headingAnchor" id="H1181555633"><span class="h1">IMPLICATIONS OF VARIANTS OF UNCERTAIN SIGNIFICANCE</span><span class="headingEndMark"> — </span>Individuals with a variant of uncertain significance (VUS) should be managed based on their personal and family history (<a class="graphic graphic_algorithm graphicRef138554" href="/d/graphic/138554.html" rel="external">algorithm 1</a>). For a VUS, new information may become available, and the testing laboratory or other resource should be consulted periodically for updates in classification (eg, annually). </p><p class="headingAnchor" id="H401184778"><span class="h1">IMPLICATIONS OF A NEGATIVE TEST</span><span class="headingEndMark"> — </span>Negative testing means no pathogenic or likely pathogenic variants were identified. However, some tests only query a subset of variants; pathogenic variants might still be present. Additional testing for other variants in <em>ATM</em> or in other genes may be needed (<a class="graphic graphic_algorithm graphicRef138554" href="/d/graphic/138554.html" rel="external">algorithm 1</a>). Referral for genetic counseling may be helpful to determine optimal testing.</p><p class="headingAnchor" id="H2697031678"><span class="h1">RESOURCES</span></p><p class="headingAnchor" id="H3850351301"><span class="h2">UpToDate topics</span></p><p class="bulletIndent1"><span class="glyph">●</span>Ataxia-telangiectasia (see  <a class="medical medical_review" href="/d/html/6233.html" rel="external">"Ataxia-telangiectasia"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Breast cancer (see  <a class="medical medical_review" href="/d/html/785.html" rel="external">"Overview of hereditary breast and ovarian cancer syndromes", section on 'ATM'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pancreatic cancer (see  <a class="medical medical_review" href="/d/html/83943.html" rel="external">"Familial risk factors for pancreatic cancer and screening of high-risk patients", section on 'Ataxia-telangiectasia'</a>)</p><p></p><p class="headingAnchor" id="H3000212508"><span class="h2">Locating a genetics expert</span></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic counselor – The National Society of Genetic Counselors (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F%3Freload%3Dtimezone&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflzQ%2BZ4POBsSFXQiuwJDn5pefBPIAES8nVSzeVi4Tr3mXQ%3D%3D&amp;TOPIC_ID=134865" target="_blank">NSGC</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical geneticist – The American College of Medical Genetics and Genomics (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=134865" target="_blank">ACMG</a>)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</li><li><a class="nounderline abstract_t">Rothblum-Oviatt C, Wright J, Lefton-Greif MA, et al. Ataxia telangiectasia: a review. Orphanet J Rare Dis 2016; 11:159.</a></li><li><a class="nounderline abstract_t">Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer Inst 1986; 77:89.</a></li><li><a class="nounderline abstract_t">Olsen JH, Hahnemann JM, Børresen-Dale AL, et al. Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries. J Natl Cancer Inst 2001; 93:121.</a></li><li><a class="nounderline abstract_t">Suarez F, Mahlaoui N, Canioni D, et al. Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies. J Clin Oncol 2015; 33:202.</a></li><li><a class="nounderline abstract_t">van Os NJ, Roeleveld N, Weemaes CM, et al. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. Clin Genet 2016; 90:105.</a></li><li><a class="nounderline abstract_t">Ahmed SR, Boucher AE, Manni A, et al. Transdermal testosterone therapy in the treatment of male hypogonadism. J Clin Endocrinol Metab 1988; 66:546.</a></li><li><a class="nounderline abstract_t">van Os NJH, Haaxma CA, van der Flier M, et al. Ataxia-telangiectasia: recommendations for multidisciplinary treatment. Dev Med Child Neurol 2017; 59:680.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN) guidelines. Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2022. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=2&amp;id=1503 (Accessed on March 29, 2022).</li><li><a class="nounderline abstract_t">Goggins M, Overbeek KA, Brand R, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 2020; 69:7.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN) guidelines: Prostate cancer early detection, version 1.2022. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=2&amp;id=1460 (Accessed on March 29, 2022).</li></ol></div><div id="topicVersionRevision">Topic 134865 Version 4.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27884168" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Ataxia telangiectasia: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3459930" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Mortality and cancer incidence in 263 patients with ataxia-telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11208881" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25488969" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26662178" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3350906" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Transdermal testosterone therapy in the treatment of male hypogonadism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28318010" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Ataxia-telangiectasia: recommendations for multidisciplinary treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28318010" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Ataxia-telangiectasia: recommendations for multidisciplinary treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31672839" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
